Payment overview · 2025
General Payments
$118.12
6 reported records · 4 companies
Healthcare provider profile · identity verified
Saagar Raju
Allopathic & Osteopathic Physicians|Family Medicine · HESPERIA, CA · NPI 1033485990
Verified facts
What the public records show
CMS Open Payments records show Saagar Raju received $118.12 in general payments during 2025 across 6 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 38.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.07 | 38.2% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.10 | 28.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.07 | 18.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.88 | 14.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $118.12 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.07 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 250 |
| Metformin Hcl | Metformin Hcl | 317 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 101 |
| Lisinopril | Lisinopril | 266 | 89 |
| Losartan Potassium | Losartan Potassium | 243 | 90 |
| Ozempic | Semaglutide | 230 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 59 |
| Omeprazole | Omeprazole | 188 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 54 |
| Trazodone Hcl | Trazodone Hcl | 131 | 53 |
| Ibuprofen | Ibuprofen | 128 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 40 |
| Gabapentin | Gabapentin | 114 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 46 |
| Glipizide | Glipizide | 98 | 34 |
| Simvastatin | Simvastatin | 97 | 35 |
| Alendronate Sodium | Alendronate Sodium | 91 | 32 |
| Famotidine | Famotidine | 88 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 29 |
| Naproxen | Naproxen | 73 | 28 |
| Furosemide | Furosemide | 72 | 22 |
| Januvia | Sitagliptin Phosphate | 72 | 14 |
| Enalapril Maleate | Enalapril Maleate | 67 | 21 |
| Meloxicam | Meloxicam | 65 | 25 |
| Eliquis | Apixaban | 56 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Allopurinol | Allopurinol | 52 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 19 |
| Montelukast Sodium | Montelukast Sodium | 52 | 16 |
| Benazepril Hcl | Benazepril Hcl | 50 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 19 |
| Carvedilol | Carvedilol | 48 | 15 |
| Nifedipine Er | Nifedipine | 48 | 13 |
| Jardiance | Empagliflozin | 47 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 16 |
| Rybelsus | Semaglutide | 43 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 12 |
| Atenolol | Atenolol | 41 | 14 |
| Buspirone Hcl | Buspirone Hcl | 41 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Lidocaine | Lidocaine | 38 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 13 |
| Methylprednisolone | Methylprednisolone | 35 | 32 |
| Finasteride | Finasteride | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 14 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tretinoin | Tretinoin | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $118.12 · 6 records | Bayer Healthcare Pharmaceuticals Inc. | CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, Kerendia, NUZYRA, ROTATEQ, VAXELIS, VAXNEUVANCE, XHANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error